Abstract

A study is being conducted to examine the effectiveness of continuous intervention in conjunction with bevacizumab in managing individuals with non-small cell lung cancer. In this study, we recruited 100 lung cancer patients who underwent treatment at our hospital between June 2020 and June 2022. Subsequently, these individuals were randomly allocated into two groups; control group and an observation group, comprising 50 patients in each group. Routine care was given to the control group, whereas the observation group received enhanced care continuously along with the routine care offered to the control group. Following a 6 mo follow-up period, the self-developed "Disease Knowledge Questionnaire" was utilized to assess the level of disease knowledge awareness in both groups. The quality of life evaluation scale was utilized to gauge the survival quality of the patients, taking into consideration their physiological, psychological, social, and health education aspects. Adverse reactions, including diarrhea, rash, nausea/vomiting, and elevated transaminases, were also monitored and documented. The observation group exhibited a notably higher disease knowledge awareness rate compared to the control group (p<0.05). Additionally, in terms of physiological, psychological, social, and health education domains, the observation group achieved remarkably better scores than the control group (p<0.05). However, no substantial difference was found in overall adverse reactions between the two groups (p>0.05). The outcomes of this research affirm the effectiveness and suitability of integrating continuous care and bevacizumab as a treatment approach for non-small cell lung cancer. By implementing continuous care measures, individuals experienced an improvement in disease knowledge awareness and an enhancement in their physiological, psychological, and social functions. Importantly, these measures did not exert a significant negative impact on the management of adverse reactions.